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Abstract  
Introduction: Wilms tumor (WT) or nephroblastoma is the commonest childhood cancer in Rwanda. Nephroblastoma is regarded as one of the 
successes of pediatric oncology with long-term survival approaching 90%. The Objectives to evaluate the feasibilityof treating childhood cancer 
using the nephroblastoma example and to calculate its cost of treatment in Rwanda. Methods: Prospective study over a 2 year period: 01 Jan 
2010- 31 December 2011.A questionnaire was completed by all participants in the study and the following variables were collected at Kigali 
University Teaching Hospital: age at diagnosis, gender, transport cost, cost of investigations, staging, treatment and outcome, cost of 
hospitalization, type of medical, surgical, radiological interventions and their costs, number of admissions per patient and factors related to non 
compliance to treatment. All patients had a confirmed diagnosis on histopathology examination. The cost for treatment was calculated for early 
and late stage and was expressed in USA dollars. Analysis was done with SPSS 16.0. Results: There were 25 patients diagnosed and treated for 
WT during the study period. Almost half of the patients 14/25 (56%) had advanced disease, seven children (28%) had stage IV, seven children 
stage III, six patients (24%) with stage II, while the remaining five (20%) had stage I with high risk tumor. The direct cost of management 
ranged from1,831.2 USD for early disease to 2,418.7 USD for advanced disease. The cost of transport, investigations and drugs were recorded as 
main contributing factors to the feasibility and cost of the treatment in 80% of the responses, followed by late presentation (56%) and poor 
compliance to treatment. Conclusion: Most challenges are related to unaffordable treatment and late presentation. The management of WT is 
feasible in Rwandan setting but efforts should be made in order to improve awareness of childhood cancer, early diagnosis and access to care. The 
government of Rwanda is committed to improve cancer care in the country and organized the first pediatric international oncology conference in 
Kigali, in March 2012 to develop National protocols for the top five most common cancers in children. 
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Introduction 
 
The nephroblastoma or Wilms tumor (WT)is the commonest solid 
childhood renal tumor, accounting for about 6% of all pediatric 
malignancies [1]. It predominantly affects children less than five 
years of age, with 90% of new cases diagnosed before age of three 
years [1, 2]. The cancer treatment in childhood is expensive 
especially in the Low-income countries with a low and very low GDP 
per capita. Cost of illness includes three categories: Direct, Indirect, 
and Psychosocial costs [3]. Typically it involves periods of 
hospitalization,time spent by physician and other professional 
services, use of laboratory and other diagnostic tests, administration 
of chemotherapy, use of other pharmaceuticals and surgical or 
radiotherapy approach. 
  
All these components impose a large financial burden on health-care 
systems and on the families of the children who are affected [4]. 
Rwanda is a Low-income country, with a GDP per capita which 
averaged 782.2 USD from 1980 until 2012 and reached an all time 
high of 1167.2 USD in December 2012 [5]. Rwanda made progress 
in reducing infection-related childhood deaths over the last two 
decades. More efforts are now directed towards addressing the 
burden of non-communicable diseases and cancer represents one of 
them.Childhood cancer is not a common disease but is curable if 
diagnosed early and treated appropriately. In this context it is 
essential to estimate the current cancer burden and the feasibility of 
treatment of childhood cancer particularly for the most frequent and 
curable types. This study on Wilms tumor at Kigali University 
Teaching Hospital is the first cost and feasibility study on childhood 




The objectives of the study were the calculation of the direct cost of 
treatment of Wilms tumor in Rwanda, the evaluation of feasibility of 






It was a hospital based prospective descriptive study of patients 
with nephroblastoma treated in the pediatric department of Kigali 
University Teaching Hospital within 2 years period from the 01 
January 2010-31 December 2011. The KUTH is located in the Center 
of Kigali city and is the main public health institution in Rwanda. 
During the study period the hospital was the only public referral 
hospital in the country where childhood cancer was diagnosed and 
treated. It serves normally one to two million people from a largely 
urban and rural area, children representing more than 40% of the 
population. 
  
The patients were followed during the period of this study, and 
readmitted several times in the Pediatric Oncology Unit 
(POU)according to their chemotherapy schedule or if there were 
other medical indications (infections, anemia or thrombocytopenia 
which needed blood or blood products transfusions, neutropenia, 
etc).The ward has a capacity of 12 beds dedicated to oncology and 
the occupation rate is almost always close to 100%.The unit admits 




All patients admitted and diagnosed with Wilms tumor at Kigali 
University Teaching Hospital from 01 January 2010 - 31 December 
2011were included in the study. Parents or legal guardians of 
children enrolled in this study signed a written consent form. 
Patients, who died before the confirmation of the diagnosis, were 




After a thorough physical examination, the routine biochemical 
panel (renal function tests, liver function tests), viral panel included 
(Hepatitis A, B, C and HIV), full blood count, urinalysis completed by 
the following imaging: chest radiography, abdominal ultrasound, 
heart ultrasonography and abdominal computer tomography (CT) 
scan were done for all patients enrolled in this study as baseline 
assessment. The patients were started on preoperative 
chemotherapy by using the SIOP 2001 Nephroblastoma protocol 
(Table 1). For surgical purpose, abdominal ultrasound was 
repeated for all cases after the preoperative chemotherapy course. 
  
In the following one to two weeks after preoperative chemotherapy, 
the patient was operated. If the time of surgery exceeded 3 weeks 
after finishing the administration of chemotherapy and the patient 
had no other contraindications to postpone the nephrectomy, the 
delay was considered surgical delay. If the time for final pathology 
report exceeded 3 weeks the delay was considered delay in 
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histopathology. The patient was readmitted in the POU after surgery 
and started on a postoperative chemotherapy depending on the 
staging report. 
  
At the beginning of treatment, opportunistic infections constituted 
the main reason of admission of the patients but once the 
chemotherapy started the side effects predominated the clinical 
picture of admissions. The routinely tests before administration of 
chemotherapy cycle were: full blood count (FBC), renal function 
tests and electrolytes. Seven to ten days after chemotherapy 
administration, patients had blood counts taken either at the 




The cost was calculated using 2010-2011 tariffs applied by the 
hospital. The cost items have been identified and activity reports 
were used for calculating the total costs using unit prices and 
occurrences. We consulted the Accounting Department of UTH-
Kigali in order to get the price of every variable concerned. It 
consisted of costs of hospitalization, chemotherapy drugs and 
supportive treatment like transfusions and intravenous fluid used, 
investigations, surgical intervention and transport fees. However the 
transport fees were not included into calculations in determining the 
total cost as it differed from patient to patient, but counted as a 
contributing factor to the treatment adherence. The cost for 
transport was calculated separately and we consulted the price of 
common bus transport regulation agency available in 2011. 
  
The total cost presented in this paper did not take in consideration 
the time spent by the medical staff with each patient or their 
salaries. The currency used was in Rwandan francs and the costs 
were converted in United States Dollars (USD) at the exchange rate 
that was on market at the end of December 2011(1 USD= 605 
RFW). 
  
Factors related to treatment compliance 
  
The data were collected on a structured standardized questionnaire 
based on the following variables recorded in the specific cancer file 
for each patient: cost of drugs and affordability of chemotherapy, 
antibiotics and supportive care, date of surgical intervention in 
relationship to the end of chemotherapy protocol, date of release of 
the pathology report, withdrawal from chemotherapy, disease stage 
at enrollment and post surgery, number of visits for investigations 
and indicated admissions. Other data that were not available in 
patient‟s records were obtained through interviews with mother or 
next kin of the patient by the Principal investigator (lack of transport 




The data collected in this study did not include any personal 
identifiers as they were stored and protected with a password. The 
data access was limited to the Principal investigator and was 
anonymously analyzed. The project proposal was presented to 
Research committee of the Faculty of Medicine and it was also 
submitted to UTH-Kigali‟s Ethical and Research committees. The 
approval letters have been obtained from both Research and Ethical 
committees. The parents or guardians of the patients signed a 





There were 25 patients (15 males and 10 females, sex ratio 1,5:1) 
diagnosed and treated for Wilms tumor in Pediatric Oncology Unit of 
Kigali University Teaching Hospital during the study period. The 
average age of our patients at presentation was 4,7 years (2-12 
years at diagnosis). The one patient who was 12 years old had the 
histology revised and confirmed by a team of pathologists. Almost 
half of the patients 14/25 representing 56% presented with 
advanced disease (stage 3 and 4) and 28% of them presented with 
metastases. 
  
The patients with the Community Health Insurance „„ Mutuelle de 
Santé ” needed to pay 10% of the total cost (the transport fee is 
not covered by the Mutuelle) therefore was not taken into 
consideration in calculating the total cost. The cost for management 
ranged from 1,831.2 US$ for early stage to 2,418.7 US$ for 
advanced disease stage (radiotherapy was not included as it is not 
available in Rwanda). The cost of medications representing 38.7%, 
laboratories 25.7% followed by in-hospital stay 16.6% were the 
most important drivers of overall costs, and were higher in the 
patients presenting with advanced disease compared to early 
presentation. The cost difference between early and late 
presentation were mainly attributed to the more intensive 
chemotherapy required for advanced stage disease thus longer in-
hospital stay, the more episodes of sepsis, anemia and 
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thrombocytopenia needing more admissions and therapy, as well as 
the laboratories work-up in due of chemotherapy side effects 
monitoring. 
  
The management of patients with Nephroblastoma at Kigali 
University Teaching Hospital was affected by several factors such as 
unaffordable treatment due to poverty representing 80% followed 
by poor compliance to treatment due to lack of transport fees in 
72% and late presentation in 56%. More than half of the mothers of 
the patients (18 out 25) described the lack of financial funds as the 
main reason for not affording the transport (Table 2). In 6 cases 
the histopathology report was released with a delay of more than 3 
weeks after the operation and 2 patients with advanced diseases 
were operated later than 2 weeks from the last preoperative 
chemotherapy due to co morbidities and severe malnutrition. 
  
During the period of 2 years, 81 children have been diagnosed with 
malignancies in the Paediatric Department of Kigali University 
Teaching Hospital. The most common pathology was 
Nephroblastoma with 25 cases, followed by Lymphoma with 20 
cases and Leukaemia with 11 cases. Abdominal distension was the 





The Wilms tumor or Nephroblastoma is the commonest childhood 
cancer in Rwanda. The peak age incidence of 2-5 years and the sex 
ratio in this study is similar to other international studies [6]. The 
distribution of the stages in Rwanda reflects the general situation of 
most patients in numerous African countries that is late and with 
advanced disease. Late presentation is a common problem in 
developing countries and may be probably related mostly to 
ignorance and poverty [7]. 
  
In addition to that, most of these children are usually first managed 
in a primary care center where facilities and qualified personnel 
needed for early diagnosis are missing. The Kigali University 
Teaching Hospital, in the period under review, was the only one 
referral public Hospital taking care of these children with cancer in 
the country therefore we received patients from all over the country 
thus transport was a vital issue adding to the cost as well as the 
delay in diagnosis; this was similar to the results reported elsewhere 
[7]. Collaborative efforts among Surgeons, Pathologists, 
Pediatricians, and Radiologists have been regarded as a major 
factor in excellent outcome from current management of WT [6,8]. 
The multidisciplinary approach was impaired in the management of 
WT in the period under review; the delay in surgical intervention 
and histopathology report was 8% and 24% respectively. The 
definitive management of WT involves surgery, chemotherapy and 
radiotherapy for the patients with advanced stage disease. In our 
study, none of our patients had radiotherapy, as radiotherapy 
machines are not available in the country. The nephrectomy was 
performed by a general surgeon. Our study highlighted the 
difference in cost of managing a patient with advanced disease 
versus early presentation. The cost difference was mainly attributed 
to the more intensive chemotherapy required for advanced stage 
disease thus longer in-hospital stay as well as the laboratories work-
up in due of chemotherapy side effects monitoring. For Rwanda a 
country with an average GDP per capita of 782.2 USD until 2012the 
management of nephroblastoma remains very expensive in our 
settings. 
  
The cost was mostly driven by the high cost of chemotherapy drugs 
and the lack of money for transport for the patients. A poor 
compliance of the treatment, following the chemotherapy regimen 
was described in similar studies in Sudan [7]. Our findings differ 
from previous studies reported in the literature due to the fact that 
pathology, radiotherapy, chemotherapy drugs, and in-hospital days 
in Rwanda are not free services or at a very minimal cost [9]. 
  
Nephroblastoma is regarded as one of the successes of pediatric 
oncology with long-term survival approaching 90% and 70% for 
localized and metastatic diseases [6, 10]. Out of 25 patients treated 
for Wilms tumor at Kigali University Teaching Hospital, five patients 
(20%) withdrew with the remaining completing the chemotherapy 
protocol. More than half of them presented with advanced disease. 
The overall survival is not known as many patients were lost to 
follow up. The rate of abandonment in our settings is a reflection of 
problems peculiar to the least developed and developing countries, 
problems with fundamental issues such as poverty, ignorance, and 





The results from our study present the real costs of the most 
common childhood cancer in Rwanda and call for awareness and 
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early diagnosis. Factors such as advance disease, poor compliance 
to treatment, poverty, expensive chemotherapy, lack of trained staff 
and multidisciplinary collaboration constitute major challenges in 
managing our cancer patients. In this context the Rwandan 
government organized an international conference in Kigali, in 2012 
with the theme: “ACTING TODAY FOR HEALTH TOMORROW”. One 
of the aims was to adopt national guidelines for the treatment of 
major childhood cancers. The management of Nephroblastoma is 
feasible in our setting with multidisciplinary collaboration but special 
efforts should be done to increase awareness, early diagnosis and to 
reduce the rate of abandonment. Free health care for children with 
cancer and establishment of collaboration with a tertiary cancer 
Center in the developed World in a form of twinning are some of the 
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Table 1: Preoperative chemotherapy SIOP 2001 
AMD 45ug/kg IVI push ¯   ¯   ¯   
VCR 1.5mg/m2 IVI push ¯ ¯ ¯ ¯ ¯ ¯ 
DOX 50mg/m2   ¯       ¯   
                  
    WEEKS 1 2 3 4 5 6 
AMD – Actinomycin; VCR – Vincristine; DOX – Doxorubicin 
 
 
Table 2: Characteristics of major obstacles of treating successfully the WT in our 
settings 
Characteristics Number % 
Lack of money for transport 18/25 72 
Lack of money for medication 20/25 80 
Delayed surgical intervention 2/25 8 
Delayed histopathology exam‟s report 6/25 24 
Withdraw from chemotherapy 5/25 20 




Figure 1: Wilms tumor and other malignancies seen in POU of the UTH-Kigali 
 
